{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:33Z","timestamp":1787020173534,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600351"],"award-info":[{"award-number":["81600351"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602762"],"award-info":[{"award-number":["81602762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["19ykpy103"],"award-info":[{"award-number":["19ykpy103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Skin cutaneous melanoma (SKCM) is one of most aggressive type of cancers worldwide. Serglycin (SRGN) is an intracellular proteoglycan that playing an important role in various tumors. However, its effect on immune infiltrates and whether it associates with survival of SKCM and SKCM-metastasis patients has not been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated SRGN expression via the databases of Oncomine, Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). The influence of SRGN expression on survival of SKCM and SKCM-metastasis patients was analyzed using TIMER database. Furthermore, the correlations between SRGN expression and immune infiltrates or gene marker sets of immune infiltrates were also analyzed via TIMER database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that the expression of SRGN in SKCM and SKCM-metastasis tissues was significantly increased compared to the normal skin tissues (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Interestingly, it was showed that lower level of SRGN expression and lower immune infiltrates of B cell, CD8+ T cell, Neutrophil, and Dendritic cell were correlated with poor survival rate of SKCM and SKCM-metastasis patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) but not SKCM primary patients. We also demonstrated that SRGN expression was positively associated with the immune infiltrates and diverse immune marker sets in SKCM and SKCM-metastasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicated that SRGN was associated with the survival of SKCM and SKCM-metastasis patients. SRGN may be a new immune therapy target for treating SKCM and SKCM-metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06849-7","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T15:03:07Z","timestamp":1588690987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaofang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daning","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"issue":"9687","key":"6849_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0140-6736(09)61397-0","volume":"374","author":"JF Thompson","year":"2009","unstructured":"Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374(9687):362\u20135.","journal-title":"Lancet."},{"issue":"12","key":"6849_CR2","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","volume":"25","author":"LA Fecher","year":"2007","unstructured":"Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606\u201320.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6849_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"48","key":"6849_CR4","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009;106(48):20429\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6849_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13073-019-0647-5","volume":"11","author":"SR Selitsky","year":"2019","unstructured":"Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, et al. Prognostic value of B cells in cutaneous melanoma. Genome Med. 2019;11(1):36.","journal-title":"Genome Med"},{"issue":"21","key":"6849_CR6","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678\u201383.","journal-title":"J Clin Oncol"},{"issue":"8","key":"6849_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"6849_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"13","key":"6849_CR9","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1074\/jbc.270.13.7437","volume":"270","author":"N Toyama-Sorimachi","year":"1995","unstructured":"Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F, Yagita H, Suzuki K, et al. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem. 1995;270(13):7437\u201344.","journal-title":"J Biol Chem"},{"issue":"37","key":"6849_CR10","doi-asserted-by":"publisher","first-page":"26792","DOI":"10.1074\/jbc.M512889200","volume":"281","author":"L Zernichow","year":"2006","unstructured":"Zernichow L, Abrink M, Hallgren J, Grujic M, Pejler G, Kolset SO. Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J Biol Chem. 2006;281(37):26792\u2013801.","journal-title":"J Biol Chem"},{"issue":"7\u20138","key":"6849_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00018-007-7455-6","volume":"65","author":"SO Kolset","year":"2008","unstructured":"Kolset SO, Tveit H. Serglycin--structure and biology. Cell Mol Life Sci. 2008;65(7\u20138):1073\u201385.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"6849_CR12","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/sj.leu.2404975","volume":"21","author":"CU Niemann","year":"2007","unstructured":"Niemann CU, Kjeldsen L, Ralfkiaer E, Jensen MK, Borregaard N. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia. 2007;21(12):2406\u201310.","journal-title":"Leukemia."},{"issue":"7","key":"6849_CR13","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/oncsis.2017.53","volume":"6","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Deng Y, Zheng G, Jia X, Xiong Y, Luo K, et al. SRGN-TGFbeta2 regulatory loop confers invasion and metastasis in triple-negative breast cancer. Oncogenesis. 2017;6(7):e360.","journal-title":"Oncogenesis."},{"key":"6849_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.matbio.2018.05.011","volume":"74","author":"P Bouris","year":"2018","unstructured":"Bouris P, Manou D, Sopaki-Valalaki A, Kolokotroni A, Moustakas A, Kapoor A, et al. Serglycin promotes breast cancer cell aggressiveness: induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling. Matrix Biol. 2018;74:35\u201351.","journal-title":"Matrix Biol"},{"issue":"6","key":"6849_CR15","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1159\/000492657","volume":"48","author":"Y Xu","year":"2018","unstructured":"Xu Y, Xu J, Yang Y, Zhu L, Li X, Zhao W. SRGN promotes colorectal Cancer metastasis as a critical downstream target of HIF-1alpha. Cell Physiol Biochem. 2018;48(6):2429\u201340.","journal-title":"Cell Physiol Biochem"},{"issue":"11","key":"6849_CR16","doi-asserted-by":"publisher","first-page":"e2456","DOI":"10.1038\/cddis.2016.287","volume":"7","author":"Q Chu","year":"2016","unstructured":"Chu Q, Huang H, Huang T, Cao L, Peng L, Shi S, et al. Extracellular serglycin upregulates the CD44 receptor in an autocrine manner to maintain self-renewal in nasopharyngeal carcinoma cells by reciprocally activating the MAPK\/beta-catenin axis. Cell Death Dis. 2016;7(11):e2456.","journal-title":"Cell Death Dis"},{"issue":"8","key":"6849_CR17","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1158\/0008-5472.CAN-10-3557","volume":"71","author":"XJ Li","year":"2011","unstructured":"Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71(8):3162\u201372.","journal-title":"Cancer Res"},{"issue":"10","key":"6849_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/febs.12179","volume":"280","author":"A Skliris","year":"2013","unstructured":"Skliris A, Labropoulou VT, Papachristou DJ, Aletras A, Karamanos NK, Theocharis AD. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013;280(10):2342\u201352.","journal-title":"FEBS J"},{"issue":"76","key":"6849_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.matbio.2017.10.008","volume":"75","author":"AD Theocharis","year":"2019","unstructured":"Theocharis AD, Karamanos NK. Proteoglycans remodeling in cancer: Underlying molecular mechanisms. Matrix Biol. 2019;75(76):220\u201359.","journal-title":"Matrix Biol"},{"issue":"2","key":"6849_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1593\/neo.07112","volume":"9","author":"DR Rhodes","year":"2007","unstructured":"Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166\u201380.","journal-title":"Neoplasia."},{"issue":"21","key":"6849_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"W1","key":"6849_CR22","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013w102.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"6849_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s13059-014-0473-4","volume":"15","author":"B Li","year":"2014","unstructured":"Li B, Li JZ. A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. Genome Biol. 2014;15(9):473.","journal-title":"Genome Biol"},{"key":"6849_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fimmu.2019.00006","volume":"10","author":"JH Pan","year":"2019","unstructured":"Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, et al. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and Colon cancers. Front Immunol. 2019;10:6.","journal-title":"Front Immunol"},{"key":"6849_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"6849_CR26","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646\u201355.","journal-title":"Clin Cancer Res"},{"key":"6849_CR27","doi-asserted-by":"crossref","unstructured":"Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst. 2016;108(11).","DOI":"10.1093\/jnci\/djw144"},{"key":"6849_CR28","doi-asserted-by":"crossref","unstructured":"Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2017;2(8).","DOI":"10.1172\/jci.insight.91438"},{"issue":"9","key":"6849_CR29","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/cncr.26511","volume":"118","author":"TO Jensen","year":"2012","unstructured":"Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Sjoegren P, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma. Cancer. 2012;118(9):2476\u201385.","journal-title":"Cancer."},{"issue":"3","key":"6849_CR30","first-page":"997","volume":"56","author":"RI Nedelcu","year":"2015","unstructured":"Nedelcu RI, Ion DA, Holeab CA, Cioplea MD, Brinzea A, Zurac SA. Dendritic cells in melanoma - immunohistochemical study and research trends. Romanian J Morphol Embryol. 2015;56(3):997\u20131002.","journal-title":"Romanian J Morphol Embryol"},{"issue":"2","key":"6849_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CMR.0000000000000333","volume":"27","author":"LS Lino-Silva","year":"2017","unstructured":"Lino-Silva LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, Zepeda-Najar C. Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma. Melanoma Res. 2017;27(2):140\u20134.","journal-title":"Melanoma Res"},{"issue":"6","key":"6849_CR32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/jso.25138","volume":"118","author":"S Kanatsios","year":"2018","unstructured":"Kanatsios S, Melanoma Project M. Li Wai Suen CSN, Cebon JS, Gyorki DE. Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. J Surg Oncol. 2018;118(6):915\u201321.","journal-title":"J Surg Oncol"},{"issue":"10","key":"6849_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078157","volume":"8","author":"A Korpetinou","year":"2013","unstructured":"Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, et al. Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One. 2013;8(10):e78157.","journal-title":"PLoS One"},{"key":"6849_CR34","doi-asserted-by":"publisher","first-page":"690721","DOI":"10.1155\/2015\/690721","volume":"2015","author":"A Korpetinou","year":"2015","unstructured":"Korpetinou A, Papachristou DJ, Lampropoulou A, Bouris P, Labropoulou VT, Noulas A, et al. Increased expression of Serglycin in specific carcinomas and aggressive Cancer cell lines. Biomed Res Int. 2015;2015:690721.","journal-title":"Biomed Res Int"},{"issue":"15","key":"6849_CR35","doi-asserted-by":"publisher","first-page":"24815","DOI":"10.18632\/oncotarget.15820","volume":"8","author":"A Roy","year":"2017","unstructured":"Roy A, Attarha S, Weishaupt H, Edqvist PH, Swartling FJ, Bergqvist M, et al. Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression. Oncotarget. 2017;8(15):24815\u201327.","journal-title":"Oncotarget."},{"issue":"17","key":"6849_CR36","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1038\/onc.2016.404","volume":"36","author":"JY Guo","year":"2017","unstructured":"Guo JY, Hsu HS, Tyan SW, Li FY, Shew JY, Lee WH, et al. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner. Oncogene. 2017;36(17):2457\u201371.","journal-title":"Oncogene."},{"issue":"2","key":"6849_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/eji.201040429","volume":"41","author":"A Skliris","year":"2011","unstructured":"Skliris A, Happonen KE, Terpos E, Labropoulou V, Borset M, Heinegard D, et al. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol. 2011;41(2):437\u201349.","journal-title":"Eur J Immunol"},{"issue":"1","key":"6849_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12865-016-0155-y","volume":"17","author":"A Roy","year":"2016","unstructured":"Roy A, Sawesi O, Pettersson U, Dagalv A, Kjellen L, Lunden A, et al. Serglycin proteoglycans limit enteropathy in Trichinella spiralis-infected mice. BMC Immunol. 2016;17(1):15.","journal-title":"BMC Immunol"},{"issue":"3","key":"6849_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1189\/jlb.1008670","volume":"85","author":"S Wernersson","year":"2009","unstructured":"Wernersson S, Braga T, Sawesi O, Waern I, Nilsson KE, Pejler G, et al. Age-related enlargement of lymphoid tissue and altered leukocyte composition in serglycin-deficient mice. J Leukoc Biol. 2009;85(3):401\u20138.","journal-title":"J Leukoc Biol"},{"issue":"6","key":"6849_CR40","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399.","journal-title":"Cell."},{"key":"6849_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fonc.2013.00327","volume":"3","author":"A Korpetinou","year":"2014","unstructured":"Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A, Karamanos NK, et al. Serglycin: at the crossroad of inflammation and malignancy. Front Oncol. 2014;3:327.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06849-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T19:07:12Z","timestamp":1620155232000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06849-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6849"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06849-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"21 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}